Journal of NeuroInterventional Surgery · 2021 · 11 citations · 11 references
MedicineNeurological SurgeryNeurosurgeryAnesthesiaCerebrovascular SurgeryVascular SurgeryCerebral Blood FlowCerebrovascular DiseaseCerebrovascular PhysiologyHypoxic-ischemic Brain InjuryStrokeStroke SurgeryBlood FlowCerebral Blood Flow AlterationsCerebral Blood Flow EffectsCerebral Blood Flow QuantificationCerebral Blood Flow RegulationHypoxic MicroenvironmentInfarct Volume QuantificationRegional Cerebral Blood Flow
BACKGROUND: Sanguinate, a bovine PEGylated carboxyhemoglobin-based oxygen carrier with vasodilatory, oncotic and anti-inflammatory properties designed to release oxygen in hypoxic tissue, was tested to determine if it improves infarct volume, collateral recruitment and blood flow to the ischemic core in hyperacute middle cerebral artery occlusion (MCAO). METHODS: Under an IACUC approved protocol, 14 mongrel dogs underwent endovascular permanent MCAO. Seven received Sanguinate (8 mL/kg) intravenously over 10 min starting 30 min following MCAO and seven received a similar volume of normal saline. Relative cerebral blood flow (rCBF) was assessed using neutron-activated microspheres prior to MCAO, 30 min following MCAO and 30 min following intervention. Pial collateral recruitment was scored and measured by arterial arrival time (AAT) immediately prior to post-MCAO microsphere injection. Diffusion-weighted 3T MRI was used to assess infarct volume approximately 2 hours after MCAO. RESULTS: =0.536; p=0.0064). Pial collateral scores improved only in Sanguinate-treated subjects and AAT decreased by a mean of 0.314 s in treated subjects and increased by a mean of 0.438 s in controls (p<0.0276). CONCLUSION: Preliminary results indicate that topload bolus administration of Sanguinate in hyperacute ischemic stroke significantly improves infarct volume, pial collateral recruitment and CBF in experimental MCAO immediately following its administration.
11